Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.48 |
| ▸ | ABAT | P80404 | 2/20 | 0.48 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL729634 | 0.89 | CA2 (0.56) | ESR1ESR2CA2CAMK2AALDH1A1 | |
| SCHEMBL4383010 | 0.87 | ESR1 (0.58) | ESR1ESR2KMT2AMEN1LTA4H | |
| Isobutyraldehyde SCHEMBL3923146 | 0.87 | TAAR1 (0.45) | ESR1ESR2CA2CAMK2AABAT | |
| SCHEMBL6364651 | 0.85 | MAOB (0.40) | ALDH1A1BLMKMT2AMEN1LMNA | |
| Tyramine SCHEMBL11249547 | 0.85 | TAAR1 (0.72) | ESR1ESR2CA2ABATKDM4E | |
| SCHEMBL4465280 | 0.83 | ESR1 (0.38) | ESR1ESR2CA2CAMK2AABAT | |
| SCHEMBL21180387 | 0.83 | ESR1 (0.61) | ESR1ESR2ALDH1A1BLMKMT2A | |
| Phenylacetaldehyde SCHEMBL27573996 | 0.82 | CA1 (0.52) | CA2CA12CA1LMNACA3 | |
| SCHEMBL5308478 | 0.82 | ESR1 (0.46) | ESR1ESR2CA2CAMK2AABAT | |
| SCHEMBL448421 | 0.80 | ESR1 (0.55) | ESR1ESR2CA2CAMK2AABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1981 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139264-A1 | Compositions And Methods For Production Of Salidroside, Icariside D2, And Precursors Of Salidroside And Icariside D2 | WHITEHEAD INST FOR BIOMEDICAL RESEARCH (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743594-A1 | METHODS AND COMPOSITIONS FOR ANALYZING MESSENGER RNA | Sanofi Vaccines US Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122038337-A | Glycosyltransferase mutant and application thereof in preparation of salidroside | 赤壁生合元科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260028684-A1 | SYSTEMS AND METHODS FOR IDENTIFYING VIRAL CONTAMINANTS | REGENERON PHARMACEUTICALS, INC. (US) | 2026-01-29 | — | — | US | claimed |
| US-12385055-B2 | Compositions and methods for production of salidroside, icariside D2, and precursors of salidroside and icariside D2 | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2025-08-12 | — | — | US | claimed |
| US-20250204562-A1 | MASKING AGENT | FUJI OIL HOLDINGS INC. (JP) | 2025-06-26 | — | — | US | claimed |
| US-20250207157-A1 | METHODS OF PRODUCING HYDROXYTYROSOL | CONAGEN INC. (US) | 2025-06-26 | — | — | US | claimed |
| CN-120138644-A | Descaling method for scaling of HPAL process nickel leaching autoclave | 宁波力勤资源科技股份有限公司 | 2025-06-13 | — | — | CN | claimed |
| US-20250179543-A1 | NORCOCLAURINE SYNTHASES WITH INCREASED ACITVITY | RIVER STONE BIOTECH INC (US) | 2025-06-05 | — | — | US | claimed |
| US-20250057888-A1 | USE OF ALVEOLAR OR AIRWAY ORGANOIDS FOR THE TREATMENT OF LUNG DISEASES AND DISORDERS | CHILDREN'S MEDICAL CENTER CORPORATION, THE | 2025-02-20 | — | — | US | claimed |
| EP-1328643-A2 | FERMENTATIVE PRODUCTION OF D-p-HYDROXYPHENYLGLYCINE AND D-PHENYLGLYCINE | DSM N.V. (NL) | 2003-07-23 | — | — | EP | claimed |
| US-6573245-B1 | Conjugate including polysaccharide which binds to cell surface of Antigen Presenting Cell, protein or peptide antigen which elicits immunogenic response when covalently attached to polysaccharide, imine-forming compound | GALENICA PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | claimed |
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | GALENICA PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | claimed |
| WO-2002034921-A2 | FERMENTATIVE PRODUCTION OF D-p-HYDROXYPHENYLGLYCINE AND D-PHENYLGLYCINE | DSM N.V. (NL) | 2002-05-02 | — | — | WO | claimed |
| EP-1107785-A1 | METHOD OF DNA VACCINATION | GLAXO GROUP LIMITED (GB) | 2001-06-20 | — | — | EP | claimed |
| EP-1027061-A4 | IMINE-FORMING POLYSACCHARIDES, PREPARATION THEREOF AND THE USE THEREOF AS ADJUVANTS AND IMMUNOSTIMULANTS | GALENICA PHARMACEUTICALS INC (US) | 2000-12-13 | — | — | EP | claimed |
| EP-1027061-A1 | IMINE-FORMING POLYSACCHARIDES, PREPARATION THEREOF AND THE USE THEREOF AS ADJUVANTS AND IMMUNOSTIMULANTS | Galenica Pharmaceuticals, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-2000012121-A1 | METHOD OF DNA VACCINATION | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| WO-1999017783-A1 | IMINE-FORMING POLYSACCHARIDES, PREPARATION THEREOF AND THE USE THEREOF AS ADJUVANTS AND IMMUNOSTIMULANTS | GALENICA PHARMACEUTICALS, INC. (US) | 1999-04-15 | — | — | WO | claimed |
| US-5508310-A | ADMINISTERING SUBSTITUTED ALDEHYDES OR KETONES WHICH CAN REACT WITH T-CELL SURFACE GROUPS TO FORM SCHIFF BASES | BURROUGHS WELLCOME CO. (US) | 1996-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028684-A1 | SYSTEMS AND METHODS FOR IDENTIFYING VIRAL CONTAMINANTS | MRPS35, RNASEL, MTREX | ESR1 2220/4885ESR2 1903/4885CA2 3046/4885 |
| US-20260139264-A1 | Compositions And Methods For Production Of Salidroside, Icariside D2, And Precursors Of Salidroside And Icariside D2 | COMT, UGDH, GUSB | ESR1 2349/4885ESR2 2785/4885CA2 1383/4885 |
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | TLR1, ICOS, TLR2 | ESR1 2111/4885ESR2 2942/4885CA2 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.